"Fundamentally Wrong": Less Than 5% Of Cancer Patients Get Access To Clinical Trials
Long R&D time-line is "unacceptable," says Memorial Sloan Kettering cancer specialist Bob Li
Source: forbes.com
📰 Project Orbis News
Page 4 - Project Orbis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Project Orbis. Real-time updates on events, politics, business and more.
What's Next For President Biden's Cancer Moonshot?
Targets include better screening and preventable cancers, says Deputy Assistant to President for the Cancer Moonshot Dr. Danielle Carnival
Source: forbes.com
FDA Grants Xtandi Priority Review for Certain Patients with Prostate Cancer
The FDA has granted a priority review for the evaluation of Xtandi as a treatment for patients with non-metastatic castration-sensitive prostate cancer.
Ahsan Arozullah Chris Boshoff Astellas Pharma Inc Head Of Oncology Development Oncology Research Drug Administration
Source: curetoday.com
Pfizer's ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma – India Education | Latest Education News | Global Educational News
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have recei
Source: indiaeducationdiary.in
Pfizer's Elrexfio tries to challenge Janssen in RRMM with FDA approval
The FDA accelerated approval for the bispecific antibody is based on the results from a single-arm Phase II study in multiple myeloma.
Source: pharmaceutical-technology.com
Pfizer's ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma
The approval of ELREXFIO is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study ELREXFIO is the first off-the-shelf fixed-dose subcutaneous... -Today at 02:09 pm- MarketScreener
Source: marketscreener.com
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...
Source: marketscreener.com
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and...
Source: globenewswire.com
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy Patients with this type of endometrial cancer face...
United Kingdom United States United Kingdom General Hesham Abdullah Matthew Powell Cerner Enviza Cancermpact
Source: marketscreener.com
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
31.07.2023 - GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for the treatment of adult ...
United Kingdom United States United Kingdom General Cerner Enviza Cerner Enviza Cancermpact Matthew Powell
Source: wallstreet-online.de